Tirzepatide vs Semaglutide: Dual Agonist vs GLP-1

Tirzepatide vs semaglutide is a comparison of two FDA-labeled incretin drugs, not two research cakes. Semaglutide hits the GLP-1 receptor. Tirzepatide hits GIP and GLP-1. One lock versus two. A pen versus a pen. A prescriber who owns the risk.

Neither is AOD-9604. Neither is a lyophilized catalog fragment. If you came here hunting a research peptide that does what the pen does, you are in the wrong aisle.

Semaglutide is a GLP-1 receptor agonist. You know the brands as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). Tirzepatide is a dual GIP and GLP-1 receptor agonist. Brands: Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Same weekly-shot neighborhood. Different lock count.

If you wanted the wider map — prescription incretins versus research-catalog fragments versus tesamorelin — that already lives on peptides for weight loss. This page is the dual-agonist versus GLP-1 lane only. Start on Start Here if you are brand new and a head-to-head drug paper is not day one.

This is education. It is not medical advice. It is not a reason to skip a clinician. It is not a reason to hunt a research vial that pretends to be the pen.

What is tirzepatide vs semaglutide, actually?

A peptide is a short chain of amino acids. Insulin is a peptide. Semaglutide is a peptide. Tirzepatide is a peptide. AOD-9604 is a peptide. Naming the format does not name the job.

Semaglutide was built to hit the GLP-1 receptor. Appetite. Gastric emptying. Glucose handling. One key. One lock.

Tirzepatide was built to hit two: the GIP receptor and the GLP-1 receptor. Dual agonist. That is the entire extra claim surface. Not “semaglutide but orange.” Not a research-catalog upgrade sticker.

Steal this filter.

Lane	What it actually is	What the evidence is	What it is not
Semaglutide	GLP-1 receptor agonist. Brands: Ozempic (T2D), Wegovy (weight management)	Large randomized programs, including STEP 1 in NEJM. Head-to-head with tirzepatide in SURMOUNT-5	Not tirzepatide. Not a research-catalog fragment. Not a DIY obesity protocol
Tirzepatide	Dual GIP + GLP-1 receptor agonist. Brands: Mounjaro (T2D), Zepbound (weight management)	SURMOUNT-1 versus placebo. SURMOUNT-5 versus semaglutide in adults with obesity without diabetes	Not semaglutide. Not retatrutide. Not something a research lab sells as a lyophilized cake
Retatrutide	Triple agonist at GIP, GLP-1, and glucagon receptors. Still in development	Phase 2 obesity data in NEJM. Not an FDA retail label like tirzepatide or semaglutide	Not a third brand next to Zepbound. Not a research-vial SKU

You can be interested in all three. You cannot mash them into one Reddit protocol and call the extra receptor a clinical result you get from a catalog.

Semaglutide: GLP-1, Ozempic, Wegovy

Semaglutide is the GLP-1 side of tirzepatide vs semaglutide. One receptor. Weekly injection in the approved products.

The brand split matters. Ozempic is the type 2 diabetes label. Wegovy is the chronic weight-management label. Same molecule family. Different indication. Different conversation with a prescriber. I am not going to pretend those labels are interchangeable because a forum thread stacked the milligrams.

STEP 1 put once-weekly semaglutide 2.4 mg against placebo in adults with overweight or obesity. Wilding and colleagues published it in the New England Journal of Medicine in 2021. That is a placebo-controlled obesity program. It is not a head-to-head with tirzepatide. It is not a reconstitution calculator.

A clinician belongs in the loop. Nausea, GI effects, contraindications, and whether a GLP-1 is even the right tool are not caption work. I am not going to tell you to skip a doctor. I am going to tell you to read the label with someone who can write the prescription.

Tirzepatide: GIP plus GLP-1, Mounjaro, Zepbound

Tirzepatide is the dual-agonist side. GIP receptor. GLP-1 receptor. Two keys.

Mounjaro is the type 2 diabetes brand. Zepbound is the chronic weight-management brand. Same dual-agonist molecule neighborhood. Different indication. If someone tells you “just get Mounjaro for fat loss off a research site,” they are mixing lanes on purpose.

SURMOUNT-1 did the placebo-controlled obesity work for tirzepatide. Jastreboff and colleagues, NEJM, 2022. Dual agonist versus placebo. That paper is why the group chat learned the word tirzepatide. It still does not answer tirzepatide vs semaglutide in the same trial.

That answer needed a head-to-head.

The head-to-head: SURMOUNT-5

Until 2025, most tirzepatide vs semaglutide arguments were people stacking two different trials and calling it science. Different populations. Different designs. Same comment section.

Aronne and colleagues published SURMOUNT-5 in the New England Journal of Medicine in 2025. Phase 3b. Open-label. Funded by Eli Lilly. 751 adults with obesity but without type 2 diabetes. Maximum tolerated tirzepatide (10 mg or 15 mg) versus maximum tolerated semaglutide (1.7 mg or 2.4 mg), once weekly, 72 weeks. Primary end point: percent change in weight.

The least-squares mean percent change in weight at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide. Waist circumference moved in the same direction: −18.4 cm versus −13.0 cm. Gastrointestinal adverse events were the most common in both groups, mostly mild to moderate, mostly during dose escalation.

Read that as a paper. Do not read it as “order tirz, skip the visit.”

Open-label means people knew which pen they were on. Lilly funded it because Lilly makes tirzepatide. Superiority on weight and waist in that population is a real result. It is still a prescription result. It is still not a research-vial protocol. It is still not medical advice from this page.

I am not going to drop units-and-days, titration schedules, or “how to get it without a doctor” on a public URL. That is how people get hurt. Full protocol depth stays in Peptides & Pump Pro on purpose. Ten dollars a month. Seven-day trial. This page is the map.

Retatrutide vs tirzepatide: the triple that is not a retail drug

Retatrutide vs tirzepatide is the next tab people open after they learn the word dual.

Retatrutide is a triple agonist. GIP. GLP-1. Glucagon. Three receptors. Tirzepatide stops at two. Semaglutide stops at one. That is the education map. Extra receptor is not extra permission to buy a white powder labeled “reta.”

Phase 2 obesity data from Jastreboff in NEJM, 2023 is the paper behind the hype. It is still a drug-development conversation. It is not an FDA-approved retail product like Wegovy, Zepbound, Ozempic, or Mounjaro. This section sticks to what is published — no invented phase 3 percentages, approval dates, or brand names.

If a catalog lists retatrutide next to AOD-9604, that catalog is not the FDA. Trials are not retail. A dual agonist with a label is not a triple agonist in a freezer.

This is not a research-peptide conversation

Lee’s partners do not sell tirzepatide. They do not sell semaglutide. They do not sell retatrutide as an obesity drug. If a screenshot told you otherwise, close it.

AOD-9604 is a 16-amino-acid hGH fragment (176-191). It was built as a lipolytic piece of the hormone. Mouse lipid-metabolism data exists. Human weight-loss data is mixed. It is not an incretin agonist. It is not a loophole around a GLP-1 label. That whole lane — research fragments versus prescription incretins versus tesamorelin — is already on peptides for weight loss. I am not going to reprint it so this URL can steal a keyword it does not own.

If someone tells you to “get tirz from a research vial,” they are asking you to treat a drug like a catalog cake. Different manufacturing. Different claims you are allowed to make. Different thing in your hand. Different legal and medical mess if it goes wrong.

If you ever reconstitute a lyophilized research vial, how to reconstitute peptides is the public math page. That article is technique. It is not a tirzepatide protocol. It is not a semaglutide protocol.

How should a beginner think about tirzepatide vs semaglutide?

Start with the question, not the brand.

Are you trying to understand why one molecule hits one receptor and the other hits two? Stay here.

Are you trying to decide whether a prescription incretin belongs in your medical plan? That is a clinician visit. Not a reconstitution calculator. Not a coupon code.

Are you trying to copy a compounding protocol from a forum because the name sounded like the pen? You are copying a shopping cart.

Here is the order I give beginners.

1. Read first. The Start Here page exists so you do not run a dual agonist on day one because a podcast guest stacked it on a whiteboard.

2. Name the receptors. Semaglutide: GLP-1. Tirzepatide: GIP + GLP-1. Retatrutide: GIP + GLP-1 + glucagon, still in trials. If you cannot say that in one breath, close the tab.

3. Separate the lanes. FDA-approved pens in the prescription bucket. Research-catalog fragments in the AOD bucket. Do not mash them because both words have “peptide” in a caption.

4. Match the job. If the job is learning tirzepatide vs semaglutide, you do not need a research vial. If the job is understanding research fat-loss peptides, go to the weight-loss hub.

5. Ask before you buy random. The free Knowledge Base is where sourcing questions belong. Pro is where the protocol library lives. Public pages like this one exist so Google stops lying to you.

Where to get AOD-9604 research vials

Education first. You already got the dual-agonist map. This block is not “buy this to treat obesity.” It is the research-catalog SKU I will put my name on when people ask about AOD-9604, the hGH fragment, not a fake GLP-1. Research-use catalog pages. Not a treatment claim. Not a substitute pen.

Limitless is the primary partner on this page for AOD-9604.

AOD-9604 research vials

Limitless AOD-9604 · LEE20Paramount AOD-9604 6mgPeptira AOD-9604 5MG · LEEBioLongevity home · LEE15

BioLongevity does not sell AOD — use their shop home with code LEE15 if you browse that catalog. S1 may list AOD; check their shop with code LEE10. Match the product to the job. Do not collect bottles. Do not buy AOD because you wanted a GLP-1.

Frequently asked questions about tirzepatide vs semaglutide

Is tirzepatide just a stronger semaglutide?

No. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. SURMOUNT-5 compared maximum tolerated doses in adults with obesity without diabetes and reported greater mean weight and waist change on tirzepatide at 72 weeks. Stronger is a bar conversation. Dual versus single is the mechanism conversation.

Are Ozempic and Wegovy the same as Mounjaro and Zepbound?

No. Ozempic and Wegovy are semaglutide brands (diabetes versus weight-management labels). Mounjaro and Zepbound are tirzepatide brands (same split). Do not mash four brand names into one Reddit protocol.

Can I get tirzepatide or semaglutide from a research peptide site?

Not from the partners I will put my name on. Those catalogs are not a substitute pharmacy. A research fragment is not a dual agonist with a label. If a GLP-1 or dual agonist is medically appropriate, that is a prescription conversation with a qualified professional.

Is retatrutide available like tirzepatide?

No. Retatrutide is a triple agonist still in trials. Tirzepatide and semaglutide have FDA-approved branded products. A phase 2 paper is not a retail drug.

Can AOD-9604 replace tirzepatide or semaglutide?

No. Different receptors. Different jobs. Different evidence piles. A lipolytic hGH fragment is not an incretin agonist. AOD-9604 is not a loophole around a drug label, a side-effect profile, or a diagnosis.

Where do full protocols live?

Peptides & Pump Pro. $10 a month. 7-day trial. This public page answers the search question. It is not a protocol. It is not medical advice. It is not a cure.

The bottom line

Tirzepatide vs semaglutide is dual agonist versus GLP-1.

Semaglutide hits GLP-1. Tirzepatide hits GIP and GLP-1. SURMOUNT-5 is the head-to-head paper. Retatrutide is the triple still in trials. None of that is a research-catalog vial, and none of this page is a substitute for a clinician.

Keep the lanes. Read the papers. Do not buy a white powder because a caption told you it was the pen.

Read next: peptides for weight loss for the research-vs-drug map, AOD-9604 if someone sold you a fragment as a pen, and MOTS-c when the mitochondrial caption is the distraction.

I built Peptides & Pump so you can get this without a guru tax. If you want the protocol library, member discussions, and a place to think out loud before you spend money, that is Pro. If you are not ready to pay, use the free Knowledge Base first. Then come back and argue with me when you have read more than a caption.

Next reads

Peptides for Weight Loss: Research Compounds vs GLP-1s

AOD-9604 is an hGH fragment; tesamorelin is a GHRH analog. Research vs prescription.

What Are Peptides? The Beginner Guide That Actually Makes Sense

Short amino-acid chains that act as signals, not proteins, steroids, or collagen powder.

MOTS-c: The Mitochondrial Peptide

A 16-amino-acid peptide encoded in mitochondrial DNA — not a GLP-1, not a GH secretagogue.

---

Supplier footnote: Research suppliers I mention when people ask about AOD-9604, not tirzepatide or semaglutide: Limitless AOD-9604 (code LEE20), Paramount AOD-9604 6mg, and Peptira AOD-9604 5MG (code LEE). BioLongevity home: LEE15. For S1, check their shop with code LEE10. Match the product to the job. Do not collect bottles.

Disclaimer. This article is for educational and research purposes only. It is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Semaglutide products (including Ozempic and Wegovy) and tirzepatide products (including Mounjaro and Zepbound) are prescription drugs; that is a clinician conversation, not a research-vial protocol. Retatrutide is an investigational triple agonist and is not an FDA-approved retail obesity drug as of this writing. AOD-9604 is not an FDA-approved weight-loss drug. Peptides & Pump does not sell peptides and does not sell tirzepatide or semaglutide. Individual results vary. Always consult a qualified healthcare provider before starting any peptide, supplement, or protocol, especially if you have a medical condition or take prescription medication.

Affiliate disclosure. Some links on this page are affiliate links. If you buy through them, I may earn a commission at no extra cost to you. Codes LEE15, LEE20, LEE10, and LEE are the ones I actually use. That commission is how I keep publishing free education. I only link suppliers I am willing to put my name on. Those suppliers are linked here for AOD-9604 research catalog pages, not as a source of tirzepatide or semaglutide.